[Successful Hematopoietic Cell Transplantation Following Azacitidine Treatment in an Acute Myeloid Leukemia Patient with t(3;3)(q21;q26.2) Translocation and Marked Thrombocythemia].
Gan To Kagaku Ryoho
; 42(8): 1013-7, 2015 Aug.
Article
em Ja
| MEDLINE
| ID: mdl-26321721
ABSTRACT
A 39-year-old man visited our department complaining of general malaise and appetite loss. He presented with anemia and marked thrombocythemia; his plasma transforming growth factor (TGF)-b concentration was markedly increased and his thrombopoietin (TPO)concentration was decreased. Since the patient's disease had progressed to acute myeloid leukemia (AML) with an increase in the peripheral blast count, he was diagnosed with AML along with t(3;3) (q21;q26.2) through a bone marrow aspiration sample. Remission induction therapy was performed using idarubicin/cytarabine. The patient achieved complete remission. His platelet count returned to the normal range, plasma TGF-b concentration decreased, and serum TPO concentration increased. The patient was treated with azacitidine as post-remission therapy for bone marrow transplantation, following which he underwent allogeneic hematopoietic cell transplantation.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Translocação Genética
/
Leucemia Mieloide Aguda
/
Transplante de Células-Tronco Hematopoéticas
/
Antimetabólitos Antineoplásicos
Limite:
Adult
/
Humans
/
Male
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
2015
Tipo de documento:
Article